Journal Article Review Epublish 18 citations
PubMed: 37568870 DOI: 10.3390/diagnostics13152508
Cardiac Biomarkers and Their Role in Identifying Increased Risk of Cardiovascular Complications in COVID-19 Patients.
Diagnostics (Basel) 13(15)
Authors: Nagendra Yaluri, Alena Stančáková Yaluri, Pavol Žeňuch, Zuzana Žeňuchová, Štefan Tóth, Peter Kalanin
Affiliations
- Center of Clinical and Preclinical Research, University Research Park Medipark, P. J. Šafárik University, 040 01 Košice, Slovakia.
- 4th Department of Internal Medicine, P. J. Šafárik University, 040 01 Košice, Slovakia.
Abstract
Cardiovascular disease (CVD) is a global health concern, causing significant morbidity and mortality. Both lifestyle and genetics influence the development of CVD. It is often diagnosed late, when the treatment options are limited. Early diagnosis of CVD with help of biomarkers is necessary to prevent adverse outcomes. SARS-CoV-2 infection can cause cardiovascular complications even in patients with no prior history of CVD. This review highlights cardiovascular biomarkers, including novel ones, and their applications as diagnostic and prognostic markers of cardiovascular complications related to SARS-CoV-2 infection. Patients with severe SARS-CoV-2 infection were shown to have elevated levels of cardiac biomarkers, namely N-terminal pro-brain natriuretic peptide (NT-pro-BNP), creatine kinase-myocardial band (CK-MB), and troponins, indicating acute myocardial damage. These biomarkers were also associated with higher mortality rates and therefore should be used throughout COVID-19 patient care to identify high-risk patients promptly to optimize their outcomes. Additionally, microRNAs (miRNAs) are also considered as potential biomarkers and predictors of cardiac and vascular damage in SARS-CoV-2 infection. Identifying molecular pathways contributing to cardiovascular manifestations in COVID-19 is essential for development of early biomarkers, identification of new therapeutic targets, and better prediction and management of cardiovascular outcomes.
MeSH
Infections, Mortality, Risk, Biomarkers, Cardiovascular Diseases, Therapeutics, Micrornas, Covid-19, Sars-Cov-2
Cited by
- Rapid-Test Kit for Cardiac Troponin I: A Reliable Enzyme-Linked-Immuno-Substrate-Assay-Based Biosensor for Daily-Use Naked-Eye Detection and Pharmacokinetic Studies for Myocardial Infarction in Cardiovascular Disease. ACS Pharmacol Transl Sci, 2024
- Genetic and Epigenetic Intersections in COVID-19-Associated Cardiovascular Disease: Emerging Insights and Future Directions. Biomedicines, 2025
- Biomarkers for SARS-CoV-2 infection. A narrative review. Front Med (Lausanne), 2025
- Novel Insights into CKMB, Myoglobin, and Troponin I Levels as Predictors of COVID-19 Severity and Hospitalization Outcomes. Biomedicines, 2025
- Advancements in Myocardial Infarction Management: Exploring Novel Approaches and Strategies. Cureus, 2023
- Quantification of Myocardial Biomarkers in Sudden Cardiac Deaths Using a Rapid Immunofluorescence Method for Simultaneous Biomarker Analysis. Biomedicines, 2025